# Novavax: Phase 4 study terminated, 6500 enrolled (COVID-19, Sars-CoV-2 Infection)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Novavax |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Efficacy and Safety of NVX-CoV2705 |
| NCT ID | NCT07086222 |
| Phase | Phase 4 |
| Status | terminated |
| Conditions | COVID-19; Sars-CoV-2 Infection |
| Intervention types | biological |
| Target enrollment | 6500 |
| Site countries | United States |
| Posted | 2025-07-25 |
| Planned start | 2025-11-20 |
| Event | Terminated |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- 6500 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07086222). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.